scispace - formally typeset
F

Francesco Lombardo

Researcher at Sapienza University of Rome

Publications -  173
Citations -  6066

Francesco Lombardo is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Sperm & Male infertility. The author has an hindex of 39, co-authored 153 publications receiving 5000 citations. Previous affiliations of Francesco Lombardo include Policlinico Umberto I & Istituto Superiore di Sanità.

Papers
More filters
Journal ArticleDOI

Study of apoptotic DNA fragmentation in human spermatozoa

TL;DR: The results suggest that apoptosis could be the final result of various pathologies and of a deregulation of spermatogenesis control systems.
Journal ArticleDOI

Full‐term pregnancies achieved with ICSI despite high levels of sperm chromatin damage

TL;DR: There is still controversy over whether analytical techniques currently in use are able to identify the level of damage to spermatozoa and large-scale studies should be conducted in different clinical settings to determine the effects of sperm DNA damage on the outcome of ART.
Journal ArticleDOI

Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility.

TL;DR: It is indicated that glutathione therapy could represent a possible therapeutical tool for both of the selected andrological pathologies and demonstrate a statistically significant positive effect on sperm motility.
Journal ArticleDOI

A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia.

TL;DR: Combined treatment with l-carnitine and l-acetyl-c Carnitine in a controlled study of efficacy was effective in increasing sperm motility, especially in groups with lower baseline levels.
Journal ArticleDOI

Use of carnitine therapy in selected cases of male factor infertility: a double-blind crossover trial

TL;DR: Based on a controlled study of efficacy, L-carnitine therapy was effective in increasing semen quality, especially in groups with lower baseline levels, however, these results need to be confirmed by larger clinical trials and in vitro studies.